Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes
Norway

PMID:21969596  

Ablation of a galectin preferentially expressed in adipocytes increases lipolysis, reduces adiposity, and improves insulin sensitivity in mice.

Ri-Yao Yang | Lan Yu | James L Graham | Daniel K Hsu | K C Kent Lloyd | Peter J Havel | Fu-Tong Liu
Proceedings of the National Academy of Sciences of the United States of America | 2011

The breakdown of triglycerides, or lipolysis, is a tightly controlled process that regulates fat mobilization in accord with an animal's energy needs. It is well established that lipolysis is stimulated by hormones that signal energy demand and is suppressed by the antilipolytic hormone insulin. However, much still remains to be learned about regulation of lipolysis by intracellular signaling pathways in adipocytes. Here we show that galectin-12, a member of a β-galactoside-binding lectin family preferentially expressed by adipocytes, functions as an intrinsic negative regulator of lipolysis. Galectin-12 is primarily localized on lipid droplets and regulates lipolytic protein kinase A signaling by acting upstream of phosphodiesterase activity to control cAMP levels. Ablation of galectin-12 in mice results in increased adipocyte mitochondrial respiration, reduced adiposity, and ameliorated insulin resistance/glucose intolerance. This study identifies unique properties of this intracellular galectin that is localized to an organelle and performs a critical function in lipid metabolism. These findings add to the significant functions exhibited by intracellular galectins, and have important therapeutic implications for human metabolic disorders.

Pubmed ID: 21969596

Research resources used in this publication

None found

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

  • Agency: NCI NIH HHS, United States
    Id: P30 CA093373
  • Agency: NIDDK NIH HHS, United States
    Id: U24 DK092993
  • Agency: NIAID NIH HHS, United States
    Id: R01 AI020958
  • Agency: NHLBI NIH HHS, United States
    Id: F32 HL009333
  • Agency: NIDDK NIH HHS, United States
    Id: RC1 DK087307
  • Agency: NIAMS NIH HHS, United States
    Id: R01 AR56343
  • Agency: NHLBI NIH HHS, United States
    Id: R01 HL09333
  • Agency: NCCIH NIH HHS, United States
    Id: AT002993
  • Agency: NCCIH NIH HHS, United States
    Id: R21 AT002993
  • Agency: NIAMS NIH HHS, United States
    Id: R01 AR056343
  • Agency: NHLBI NIH HHS, United States
    Id: R01 HL075675
  • Agency: NIDDK NIH HHS, United States
    Id: DK087307

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


MMPC-University of California Davis (tool)

RRID:SCR_015357

Center that provides the scientific community with metabolic and physiologic phenotyping tests, services, and procedures for mouse models of diabetes, diabetic complications, obesity and related disorders in order to advance medical and biological research.

View all literature mentions